Method for enhancing level of work capacity of laboratory animals in experiment

FIELD: medicine.

SUBSTANCE: one hour before conducting Porsolt's tests and the vertical screen-grid animals are orally given a solution voluntarily using a pipette containing 4 g of creatine monohydrate and 5 g of honey per 100 ml of distilled water, at a dose of 5 ml per 1 kg of body weight.

EFFECT: expansing the arsenal of means of actoprotective action while minimizing the pain and suffering of laboratory animals in experiment.

2 tbl, 2 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: biocompatible implant (BI) made of magnetic material in a biocompatible matrix (BM) is placed loosely along a posterior surface of an injured spinal cord of an experimental animal (EA) The EA is immersed periodically into a constant magnetic field. Its magnetic vector is aligned with a craniocaudal direction of spinal tracts. The BM of the BI is animal or herbal gelatine, wherein ferromagnetic magnetite or ferromagnetic ferrite nanoparticles 18-42 wt % with a particle size of 2.0-38 nm and at a magnetic field intensity (N) of 5-10 mT are immobilised as a magnetic material of the BI. The magnetic exposure covering the traumatic spinal injuries involves the combined effect of the magnetic field of the BI and the external rotating magnetic field at a magnetic induction of 0.15-0.35 T. The external magnetic exposure frequency is 1 or 2 times a day; the length is from 2 to 8 minutes per one session; the number of sessions is from 2 to 4. Animal gelatine in the BM of the BI can represent agar-agar, whereas herbal gelatine is pectin. The BM of the BI can additionally contain polyamines contributing to cell growth and proliferation, e.g. spermine or spemidine, in an amount of 1-5 wt %.

EFFECT: method enables recovering the spinal cord function sufficiently completely in the distal direction from the injury region, providing the favourable conditions for the adequate neuroglial growth with recipient's long neuron penetration from the intact proximal portion of the spinal cord into the distal one to ensure its conductive function, reducing the cicatrisation within the spinal injury, and eliminating the cerebral tissue oedema.

3 cl, 8 ex

FIELD: medicine.

SUBSTANCE: to a laboratory animal - rat - carried out is a unilateral nephrectomy, denervation and delymphatisation of the second kidney. After that the renal artery and vein are clamped for 40-60 minutes. After carrying out the surgical operation the triple immunisation of the laboratory animal with a kidney antigen, obtained from the removed kidney is carried out by an adjuvant method. 5 weeks before the surgical operation sampling of bone marrow cells from the laboratory animal is carried out, a culture of multipotent mesenchymal stromal cells is obtained from them in vitro. The denervation and delymphatisation of the remaining kidney is carried out by the removal of the adventitia and cellular tissue, wrapping the ureter, renal artery and vein, in the area of the hiluses renalis at a distance of 7-10 mm and decapsulation of the kidney in the area of its medial edge 7-10 mm wide, extension from one pole of the kidney to the other with the capture of the area of its hiluses. To obtain the kidney antigen the safe kidney is applied and the content of protein in it is brought to 70 mg/ml. On 35-40 day after carrying out the surgical operation the obtained culture of the multipotent mesenchymal stromal cells is introduced to the same animal intravenously in a dose of 1.5-3.0 mln cells in 1 ml of physiological solution.

EFFECT: method makes it possible to create an adequate, available for execution model of chronic rejection in autologous kidneys in small laboratory animals with an accelerated development of visualised destructive post-transplantation processes.

1 ex, 1 tbl, 9 dwg

FIELD: medicine.

SUBSTANCE: chemical burn is simulated in laboratory rats. From the 5th day following the simulation, therapeutic agents are administered abdominally. That involves using cefotaxime 100 mg/kg for 7 days. Prednisolone is administered in a dose of 1 mg/kg for 3 days. 3% Xymedone is administered in a dose of 30 mg/kg once a day for 40 days.

EFFECT: effective treatment of burns of the oesophagus and stomach by fast recovery of the thickness of a muscular layer of the mucous tunic and prevention of cicatrisation.

1 tbl, 16 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment tests, namely to production tests of joint implants with a metal friction pair the state of which is assessed in the course of testing with using electric (electrically resistive) diagnostic techniques. The diagnostic technique for joint implants with the metal friction pair consisting in the fact that the implant is mounted in a test bench loaded with axial force; a lubricant layer is formed between surfaces of the implant components, and the physical characteristics of the surface layer of the components in the friction zone are measured. Small AC current is passed through the friction zone of the implant; a temporary function of complex impedance of the implant tribocoupling is recorded; it uses its active and reactive component parameters to show an actual thickness of the lubricant layer and a lubricant type prevailing in the tribocoupling and a friction regimen. The actual technical condition of the joint implant tribocoupling is assessed by a ratio of the time intervals when the active part of the complex impedance is more than the reactive part to the total measurement time.

EFFECT: invention provides shortening the test time, assessing the real time of the contact of the friction surfaces, increasing the produced valid signal power and noise stability, in obtaining the objective initial diagnostic information from the friction zone in order to predict a durability of the joint implant with the metal friction pair.

5 dwg

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: limb ischemia is simulated in a male Wistar rat anaesthetised with chloral hydrate in a dose of 250-300 mg/kg by the surgical removal of femoral, popliteal arteries and the front shin artery. That is followed by introducing a prepared mononuclear fraction of the autologous bone marrow in a dose of 4×106 cells in an amount of 200 mcl. The above is introduced into the ischemic limb from two points in an amount of 100 mcl each. One point is found directly under the femoral arch paravasally within the anatomical position of collaterals of the inner iliac artery and its branches. The other point is located in the calf muscle on an anteriolateral surface of the midleg.

EFFECT: more effective experimental treatment ensured by stimulating the collateral blood flow in the ischemic limb and improving the arterial blood flow from the proximal to distal parts of the limb.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method consists in a single administration of a mixture consisting of a rat's homogenised myocardial tissue - 25%, egg albumin - 25% and Freund's adjuvant - 50%, into old male rats. The method involves administering in an amount of 0.3 ml into 5 injection points: intraperitoneally, into inguinal and axillary regions from the left and right.

EFFECT: being easy to reproduce and cost efficient, the method is effective for creating a model aiming at a possibility of studying the pathogenesis, preventing and treating cardiopathy.

2 dwg, 1 tbl, 1 ex

Phantom test // 2555129

FIELD: medicine.

SUBSTANCE: phantom test consists of two parts being a single whole. One part has a constant longitudinal height, while the other part has a continuously varying longitudinal height forming a wedge. On the side of the wedge, there are calibrated notches.

EFFECT: more accurate determination of the bone mineral density by X-ray images formed with the help of a general-application X-ray machine, and simplifying the design.

7 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to gastroenterology, pathologic physiology, and concerns simulating acute pancreatitis. To this effect, the method involves ligaturing the main truck of the excretory duct of the pancreas, administering an aggressive solution into the pancreatic duct system, and removing the ligature. The aggressive solution represents 1% chenodeoxycholic acid with 5% sodium hydrogen carbonate in an equal proportion in an amount of 0.3-0.5 ml at 10-15 mg/kg of the animal's body weight.

EFFECT: method enables developing a model of acute fatty, hemorrhagic or mixed pancreatitis in the animal that makes it applicable for improving the known methods for conservative and radical methods of treating.

15 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to ophthalmology, and concerns simulation in vivo of cortical cataract. That is ensured by a double-side surgical sympathectomy by excising a superior cervical sympathetic ganglion.

EFFECT: by simplicity and effectiveness of modulation, the method provides forming the cortical lens-form opacity, which is morphologically and immunohistochemically identical to lens cell changes in age-related lens opacity in a human.

6 dwg, 2 tbl

FIELD: veterinary medicine.

SUBSTANCE: treatment is carried out with an aqueous solution of the preparation "Biopag-D" at a concentration of 4-2% by drifting animals through the baths with the solution having the immersion depth up to the carpal joint.

EFFECT: invention enables to treat efficiently and stress-free and prevent treatment of diseases of hooves and dew claws of animals.

3 cl, 5 dwg, 4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapeutic dentistry, and can be used for the local treatment of chronic gingivitis caused by tobacco smoking in young individuals. That is ensured by a preparatory procedure of luminal-dependent chemiluminescence of the oral fluid aiming at a maximum burst and a glow light sum. If the maximum burst falls within the range of 3.3 to 18.15 standard units, whereas the glow light sum ranges from 8.2 to 40 standard units, an antioxidant therapy is conducted by using a transverse gingival mucosa electrophoresis on 5% aqueous propolis by means of jaw electrodes in a tray at a current intensity of 0.5-1 mA and an exposure of 8-10 minutes. A polarity is alternated with a positive pole to be taken the first. The therapeutic course makes 4 procedures every second day. Colgate Propolis Toothpase and Mouthwash are used additionally during 30 days. If the maximum burst is from 0.8 to 1.24 standard units, whereas the glow light sum ranges from 3.34 to 7.5 standard units, a pro-oxidant therapy is required by using an exposure to magnetic infrared laser (MIL) light covering a projection of gums and generated by Optodan laser with a periodontal attachment The exposure parameters: 2-2,000 Hz in segments, 2 minutes per each segment, no more than 12 minutes per 1 procedure. The therapeutic course makes 4 procedures every second day. Parodontax Toothpase and Mouthwash are used additionally during 12 days.

EFFECT: method simplifies and reduces the length of the treatment in the given category of patients.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula I, where A represents O; R1 is selected from phenyl or pyrimidine, which are optionally substituted with R11; R2 represents phenyl, which is optionally substituted wby 1-3 ring carbon atoms with similar or different substituents R22, R11 represents halogen; R22 is selected from hydroxy group, (C1-C4)-alkyl, which is optionallysubstituted with 1-3 atoms of fluorine, (C1-C4)-alkyloxy, (C1-C4)-alkyl-S(O)m-; m equals 2. Invention also relates to pharmaceutical composition, which contains formula I compounds, and to method of obtaining formula I compounds.

EFFECT: formula I compounds, intended for activation of EDG-1 receptor and applied for wound healing.

15 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula (I), where A represents O; X represents (C1-C6)-alkanediyl or (C1-C6)-alkanediyloxy, where oxygen atom of (C1-C6)-alkanediyloxy is bound to group R2; Y represents pyrrolidinyl; R1 represents (C1-C4)-alkyl; R2 represents phenylene, optionally substituted by one or two carbon atoms in ring with similar or different substituent R22; R3 is selected from group, which consists of cycloalkyl-CuH2u-, where u equals 1; radical of saturated 3-10-member monocyclic ring, phenyl or pyridyl, where ring radical is optionally substituted by one or two carbon atoms of ring with substituent R31; R4 represents hydrogen; R22 represents (C1-C4)-alkyl; R31 is selected from group, which consists of halogen and (C1-C4)-alkyl. Invention also relates to (S)-l-[2-(2,6-dimethyl-4-{5-[methyl-(3,3,3-trifluoropropyl)amino]-7-propoxyoxazolo[5,4-d]pyrimidine-2-yl}phenoxy)acetyl]pyrrolidine-2-carboxylic acid, pharmaceutical composition and to method of obtaining compounds of formula (I) .

EFFECT: compounds of formula (I), intended for activation of EDG-1 receptor and applied for wound healing.

16 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary and can be applied in animal-breeding for stimulation of metabolic processes, and growth activity of calves. Medication for stimulation of metabolic processes and growth activity of calves includes succinic acid as energetic stimulator, with application of citric acid as activator of succinic acid, beetroot molasses as carbon component, and methionine and sodium chloride as stimulators of digestion system.

EFFECT: application of invention makes it possible to ensure expressed acceleration of growth energy in early postnatal period.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: cytoflavin is administered into laboratory animals (rats) daily immediately before overheating in an air laboratory thermostat at +40±1-2°C for 45 minutes. The preparation is administered intraperitoneally in a dose of 100 mg/kg of body weight for 14 days.

EFFECT: higher body adaptability by increasing antioxidant activity and reducing a rate of lipid peroxidation products accumulation with underlying thermal exposure.

4 tbl

FIELD: medicine.

SUBSTANCE: minor amputation of the foot with the further necrectomy is performed. After the application of an antimicrobial bandage and drainage, the wound is hermetised from the environment by the creation of a negative pressure above the wound in a combination with drug treatment. The reatment is performed in two steps. At the first step the wound with the antimicrobial bandage and drainage is first hermetised from above with an adhesive film, with the creation and support of the negative pressure not lower than 80 mm Hg. Urokinase 500000 U is additionally introduced daily intravenously by drop infusion per 100 ml of physiological solution, Vessel-Due-F in a dose of 600 LU per 100 ml of physiological solution and VAP 20 - alprostadil in a dose of 40 mcg per 100 ml of physiological solution. In addition Antistax in capsules is introduced to the patient. At the second stage active 24-hour vacuum aspiration with the change of the negative pressure from 10 to 80 mm Hg within a day is carried out. Additionally introduced is Vessel-Due-F in a dose of 1 capsule with 250 LU 2 times per day between meals and Antistax. At the first and second stages Antistax is introduced in a dose of 2 capsules in the morning 30-40 minutes before meal, daily. Duration of each stage constitutes not less than 7 days.

EFFECT: increase of the treatment efficiency due to the complete and timely purification of the wound from pathological exudates, elimination of the progression of the purulent-necrotic process, increase of the regenerative activity of tissues, activation of local immunity, recovery of microcirculation and oxygenation of the affected tissues.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves professional oral hygiene is carried out consisting in ultrasonic removal of supra- and subgingival dental deposits and polishing of supragingival teeth. Bite splinting and recovery of dentition integrity may be required. After dissecting a mucoperiosteal flap according to the known technique, an incision area is sanitated by means of a photodynamic therapy (PDT). The PDT is conducted with the use of a diode laser at wave length 660±5 nm and emitting power 0.5-1.0 Wt. The photosensitiser "Photoditasin" in the form of 0.5% gel is introduced by means of a cannula into dental gaps, under the dissected segments of the flap and onto the mucosal tissue for 5 minutes. The photosensitiser is washed out, and the gingival pockets are repeatedly exposed to laser light for 2-3 min in the same environment. Sterile osteoplastic material is introduced into bone defects, and the flap is sutured together.

EFFECT: effective cleansing of the surgical area, eliminating the periodontal inflammation, stimulating tissue osteogenesis and regeneration, stabilising the processes of bone tissue absorption of alveolar interdental septa and preserving the tissues.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: to correct pathologic changes in the condition of viable offspring under a cytostatic impact the medication glutoxim is introduced to female rats in a dose of 50 mcg/kg 5 days before and 5 days after the introduction of the cytostatic medication vepesid. The latter is introduced once intravenously in a maximal tolerable dose, equal to 30 mg/kg. It has been established that glutoxim can be applied as means for the correction of pathologic changes in the viable offspring of rats, obtained from coupling 3 months after the cytostatic impact.

EFFECT: application of glutoxim as the means of corrective therapy makes it possible to increase efficiency and reduce its side effects.

6 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to compositions and methods of delivering water-soluble and lipid-soluble nutrients. A liquid nutritional composition contains an emulsion which contains docosahexaenoic acid, where the emulsion is dispersed in an aqueous component containing at least one of amino acid components selected from a group consisting of: arginine, arginyl-glutamine and alanyl-glutamine; and a protein surfactant containing at least about 90 wt % α-lactalbumin. The α-lactalbumin is present in an amount between about 0.1% and about 1.0% of the nutritional composition. Disclosed is a method for supplemental feeding of a subject, which includes administering said liquid nutritional composition to the subject. The subject can be a premature infant.

EFFECT: invention enables to prevent or correct nutritional deficiency in subjects in need of low-volume supplemental feeding, such as premature infants.

20 cl, 1 dwg, 3 tbl

Up!